Literature DB >> 8780516

New aspects on membrane lipid regulation in Acholeplasma laidlawii A and phase equilibria of monoacyldiglucosyldiacylglycerol.

A S Andersson1, L Rilfors, M Bergqvist, S Persson, G Lindblom.   

Abstract

A new membrane lipid, monoacyldiglucosyldiacylglycerol (MADGlcDAG), was recently discovered in Acholeplasma laidlawii strain A-EF22, demanding a new study of the biosynthetic regulation, and the phase behavior, of the glucolipids in this organism. The only liquid-crystalline phase formed by MADGlcDAG is a reversed hexagonal phase. A. laidlawii A-EF22 synthesizes four lipids that have the ability to induce the formation of reversed nonlamellar phases: MADGlcDAG, monoglucosyldiacylglycerol (MGlcDAG), monoacylmonoglucosyldiacylglycerol (MAMGlcDAG), and diacylglycerol (DAG). A Cn value of approximately 16 seems to be a critical value for the fractions of these lipids in the membrane: the fractions of MADGlcDAG and MGlcDAG are largest when the Cn values are lower than 16, while the fractions of MAMGlcDAG and DAG are largest when the Cn values are higher than 16. The fraction of nonlamellar-forming lipids was 55 mol% when the Cn value was 14.8 and the degree of unsaturation was 33 mol%. This fraction was reduced to 7 mol% when the Cn value and the degree of unsaturation were increased to 17.8 and 92 mol%, respectively, i.e., at conditions that markedly favor the formation of reversed nonlamellar phases. These observations convincingly show that a balance between lamellar- and nonlamellar-forming lipids is maintained in the membrane and strongly support the validity of the lipid regulation model proposed by us. From earlier biochemical data, obtained with short acyl chains, that were difficult to reconcile with our regulation model, it could be predicted that a lipid ought to be synthesized that assists MGlcDAG to maintain the nonlamellar-forming properties with the short chains. It is shown in the present work that this lipid is MADGlcDAG and that the regulation of the balance between lamellar- and nonlamellar-forming lipids is even more complex and sophisticated in A. laidlawii A-EF22 than previously proposed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780516     DOI: 10.1021/bi960561w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Expression and characterization of a Mycoplasma genitalium glycosyltransferase in membrane glycolipid biosynthesis: potential target against mycoplasma infections.

Authors:  Eduardo Andrés; Núria Martínez; Antoni Planas
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

Review 2.  Structure-function relationships of membrane-associated GT-B glycosyltransferases.

Authors:  David Albesa-Jové; David Giganti; Mary Jackson; Pedro M Alzari; Marcelo E Guerin
Journal:  Glycobiology       Date:  2013-11-18       Impact factor: 4.313

3.  Influence of membrane-spanning alpha-helical peptides on the phase behavior of the dioleoylphosphatidylcholine/water system.

Authors:  S Morein; E Strandberg; J A Killian; S Persson; G Arvidson; R E Koeppe; G Lindblom
Journal:  Biophys J       Date:  1997-12       Impact factor: 4.033

4.  Interaction of phosphatidylserine synthase from E. coli with lipid bilayers: coupled plasmon-waveguide resonance spectroscopy studies.

Authors:  Z Salamon; G Lindblom; L Rilfors; K Linde; G Tollin
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

5.  Total lipids with short and long acyl chains from Acholeplasma form nonlamellar phases.

Authors:  A S Andersson; L Rilfors; G Orädd; G Lindblom
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

Review 6.  Molecular biology and pathogenicity of mycoplasmas.

Authors:  S Razin; D Yogev; Y Naot
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

7.  Biophysical regulation of lipid biosynthesis in the plasma membrane.

Authors:  Stephen H Alley; Oscar Ces; Richard H Templer; Mauricio Barahona
Journal:  Biophys J       Date:  2008-01-11       Impact factor: 4.033

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.